Otsuka Pharmaceutical has pulled an application in Europe to get an extension on the label for its big-selling antipsychotic Abilify, partnered elsewhere with Bristol-Myers Squibb. Otsuka ...

Investors must wait until probably next year to find out exactly what the withdrawal of Abilify's European marketing application means for Targacept Inc.'s chances overseas with lead asset TC-5214 in ...

Abilify (aripiprazole) is a prescription atypical (second-generation) antipsychotic that treats depression, schizophrenia, and bipolar disorder. It also treats irritability related to autism and ...

The study's primary endpoint showed Abilify Maintena significantly delayed the time to recurrence of any mood episode in adults having a manic episode at screening vs. placebo. Otsuka and Lundbeck ...